North America AI in Oncology Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America AI in Oncology Market: by Type (Machine Learning, Natural Language Processing, Computer Vision, Context-Aware Computing), Application (Diagnosis, Prognosis, Imaging & Diagnostics, Therapy Planning, Clinical Trials, Patient Monitoring), Distribution Channels (Direct Sales, Distributors, Online Channels, Hospitals, Specialty Clinics, Others), Technology (Deep Learning, Machine Learning, Computer Vision, NLP, Context-Aware Computing, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20336 | Author: Clara
North America AI in Oncology Market Outlook (2025-2035)
The North America AI in Oncology market is transforming cancer care with advanced technologies enabling earlier detection, improved prognosis, and personalized treatments. Integrating AI-driven solutions such as machine learning, natural language processing, and computer vision supports medical professionals in diagnosing and managing oncology cases with improved accuracy and efficiency. The increasing prevalence of cancer, rising data volumes, and growing demand for cost-effective treatment are fueling market growth. Major players are leveraging AI to streamline workflows, accelerate drug discovery, and improve patient outcomes. Continuous technology advancements, supportive regulatory frameworks, and strategic industry collaborations are further enriching the landscape, positioning North America as a leader in AI-enabled cancer solutions.
Latest Market Dynamics
Key Drivers
Rising Cancer Incidence & Data Explosion: The increasing prevalence of cancer cases in North America is fueling the demand for AI-driven solutions that can quickly process clinical, radiological, and genetic data for accurate and timely diagnosis. For instance,
leverages advanced analytics and machine learning to provide oncologists with data-driven insights in real time (2024).
Advancements in Diagnostic Imaging: Enhanced imaging techniques powered by AI are enabling precise identification and categorization of tumors. GE Healthcare, for example, launched AI-enabled imaging solutions in June 2024, improving diagnostic accuracy and workflow efficiency.
Key Trends
Personalized Medicine Adoption: AI-driven personalized treatment planning is gaining traction. Flatiron Health's AI oncology platform is increasingly used for tailoring therapies based on patient-specific omics and clinical data (2024).
Integration of AI in Remote Patient Monitoring: Companies like Medtronic expanded remote oncology monitoring in July 2024, utilizing AI for early detection of complications and continuous monitoring, reflecting the growing trend toward telemedicine and digital care.
Key Opportunities
Expansion of AI in Clinical Trials: The use of AI to identify eligible patients and optimize clinical trial design is expanding. Google Health, partnering with cancer research centers in 2024, has demonstrated AI-based patient matching, accelerating oncology research.
AI-Driven Drug Discovery: Pharmaceutical collaborations with AI firms for rapid drug discovery offer significant potential. Roche Diagnostics’ alliance with PathAI in August 2024 streamlines biomarker discovery and oncology drug targeting.
Key Challenges
Data Privacy and Security Concerns: Patient data security remains a significant challenge. IBM Watson Health faced increased scrutiny in mid-2024 regarding compliance with evolving privacy regulations, requiring enhanced cybersecurity strategies.
Integration with Legacy Systems: Many hospitals still operate with outdated IT infrastructure, slowing seamless AI adoption. Siemens Healthineers is addressing integration issues through modular, interoperable AI platforms (2025).
Key Restraints
High Implementation Costs: The initial capital required for AI adoption is restraining smaller clinics. Enlitic reports that despite evident ROI, upfront expenses remain a primary obstacle for widespread AI deployment (2025).
Regulatory Hurdles and Approval Delays: Stringent regulatory processes slow market introduction. Aidoc’s AI solution faced FDA approval delays in late 2024, affecting speed to market.
North America AI in Oncology Market Share by Type, 2025
In 2025, Machine Learning forms the cornerstone of North America’s AI in Oncology market, accounting for the largest market share. Its ability to process vast volumes of healthcare data with sophisticated pattern recognition levels makes it the preferred choice for both diagnostic and therapeutic applications. Computer Vision closely follows, driven by the surge in imaging-based cancer detection and diagnostics. Natural Language Processing is gaining traction, particularly as unstructured clinical documentation needs accurate extraction and analysis for decision-making. Context-Aware Computing and Deep Learning, while not as dominant, collectively enhance the ecosystem by enabling real-time data-driven decision support and complex image analysis.
North America AI in Oncology Market Share by Applications, 2025
In 2025, Imaging & Diagnostics leads the application segments within the North America AI in Oncology market, emphasized by a robust adoption of AI-powered radiology and pathology solutions. Diagnosis and Therapy Planning follow, leveraging machine learning to ensure early cancer identification and optimal care pathways. Patient Monitoring, though less dominant, is exhibiting the fastest growth rate due to the proliferation of wearable devices and digital health platforms. The increased focus on real-world evidence generation in clinical trials is also propelling the use of AI within research settings, while Prognosis applications round out this multifaceted market, highlighting AI’s crucial role across the oncology continuum.
North America AI in Oncology Market Revenue (USD Million), 2020-2035
From 2020 to 2035, the North America AI in Oncology market displays exponential revenue growth. Valued at around $1,120 million in 2025, the market is forecast to surge driven by AI integration in hospitals, widespread use in diagnostics, and a shift toward personalized medicine. The adoption curve steepens post-2028 as reimbursement models and regulatory pathways improve, while technological advancements further bolster uptake. By 2035, projections suggest revenues exceeding $6,700 million, underlining the market’s critical role in revolutionizing cancer care through AI innovation. This substantial revenue trajectory showcases both the short- and long-term strategic importance of the sector.
North America AI in Oncology Market YoY Growth (%), 2020-2035
Year-over-year growth in the North America AI in Oncology market remains robust, especially from 2025 onward. After a steady CAGR of around 12-14% in the early years, growth accelerates to more than 18% yearly post-2028, reflecting increasing adoption across regional hospitals and specialized clinics. Peak expansion is estimated around 2030 as healthcare systems integrate AI-driven personalized medicine and decision support tools, before moderating as the market matures. Sustained investment, regulatory clarity, and higher digital adoption rates ensure consistent double-digit YoY gains for most of the period in review.
North America AI in Oncology Market Share by Country, 2025
In 2025, the United States dominates the North America AI in Oncology market, accounting for the lion’s share due to advanced healthcare infrastructure, significant investments in AI research, and active government support. Canada’s market share reflects steady adoption, driven by favorable regulatory environments and robust cancer care networks. Mexico, though trailing in share, is exhibiting rapid catch-up growth as more oncology centers embrace AI-driven diagnostic and therapeutic applications.
North America AI in Oncology Market Players Share, 2025
In 2025, leading technology and healthcare companies dominate the competitive landscape. IBM Watson Health holds the largest share, given its wide clinical deployment, while Siemens Healthineers and NVIDIA Corporation are strengthening their positions with innovative imaging and computational platforms. The market remains dynamic, with new entrants and smaller firms like PathAI and Flatiron Health also gaining ground through niche AI solutions for cancer diagnostics and research.
North America AI in Oncology Market Buyers Share, 2025
Hospitals are the primary buyers of AI in Oncology solutions in North America for 2025, reflecting their pivotal role in integrating new technologies for improved patient outcomes and operational efficiencies. Specialty clinics are next, benefiting from dedicated oncology programs and focused patient care approaches. Direct purchases by research institutions and clinical trial networks also contribute significantly, emphasizing the diversity of buyers in this vibrant market.
June 2024: GE Healthcare launched an advanced AI-powered imaging suite for oncology diagnosis, offering real-time image interpretation for radiologists.
July 2024: Medtronic expanded its AI-enabled remote oncology monitoring platform across North American specialty clinics for comprehensive patient management.
August 2024: Roche Diagnostics and PathAI entered a partnership to accelerate AI-driven biomarker discovery for oncology drug development.
September 2024: Flatiron Health integrated advanced personalized treatment optimization features into its oncology decision support system.
October 2024: Siemens Healthineers announced the interoperable release of their next-gen modular AI platform, simplifying integration with legacy hospital systems.
Frequently Asked Questions
About the Author
Clara
Senior Market Research Analyst
Clara is a Senior Market Research Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Clara brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Clara has helped organizations translate data into actionable growth strategies.
